Paul Feuerstadt
Overview
Explore the profile of Paul Feuerstadt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allegretti J, Feuerstadt P, Knapple W, Orenstein R, Pinton P, Sheh A, et al.
Inflamm Bowel Dis
. 2025 Jan;
PMID: 39862395
Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI)...
2.
Lembo A, Staller K, Boules M, Feuerstadt P, Spalding W, Gabriel A, et al.
Therap Adv Gastroenterol
. 2024 Dec;
17:17562848241299731.
PMID: 39664231
Background: Prucalopride (1 or 2 mg once daily) is approved for treating adults with chronic idiopathic constipation (CIC). Objectives: We determined the effect of age, body mass index (BMI), and...
3.
Shen B, Abreu M, Cohen E, Farraye F, Fischer M, Feuerstadt P, et al.
Gastrointest Endosc
. 2024 Oct;
101(2):295-314.
PMID: 39425706
Endoscopy plays a key role in diagnosis, monitoring of disease activity, assessment of treatment response, dysplasia surveillance, postoperative evaluation, and interventional therapy for patients with inflammatory bowel disease (IBD). Clinical...
4.
Allegretti J, Kelly C, Louie T, Fischer M, Hota S, Misra B, et al.
Gastroenterology
. 2024 Oct;
168(2):357-366.e3.
PMID: 39366468
Background & Aims: Recurrent Clostridioides difficile infections (CDIs) remain common. While novel microbiome therapeutics gain approval, the efficacy of a full-spectrum, oral microbiome therapeutic is unknown. This study aimed to...
5.
Cash B, Lu M, Lembo A, Feuerstadt P, Nguyen L, Terasawa E, et al.
J Manag Care Spec Pharm
. 2024 Sep;
30(10):1136-1148.
PMID: 39321115
Background: At present, 4 prescription therapies have been approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation (CIC) in adults. Objectives: To compare persistence...
6.
Boustany A, Feuerstadt P, Tillotson G
Adv Ther
. 2024 Sep;
41(11):3982-3995.
PMID: 39276186
This paper explores the intricate relationship between depression, gut dysbiosis, and Clostridioides difficile infections, collectively termed "The 3 Ds". Depression is a widespread mental disorder increasing in prevalence. It is...
7.
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, et al.
Infect Dis Ther
. 2024 Aug;
13(10):2209-2210.
PMID: 39212853
No abstract available.
8.
Feuerstadt P, Chopra T, Knapple W, Van Hise N, Dubberke E, Baggott B, et al.
Clin Infect Dis
. 2024 Aug;
80(1):43-51.
PMID: 39180326
Background: The aim of this study was to evaluate the safety and efficacy of fecal microbiota, live-jslm (RBL; REBYOTA)-the first single-dose, broad consortia microbiota-based live biotherapeutic approved by the US...
9.
Chaar A, Yoo J, Nawaz A, Rizwan R, Agha O, Feuerstadt P
Ann Gastroenterol
. 2024 Jul;
37(4):442-448.
PMID: 38974087
Background: Frailty has major health implications for affected patients and is widely used in the perioperative risk assessment. The Hospital Frailty Risk Score (HFRS) is a validated score that utilizes...
10.
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, et al.
Infect Dis Ther
. 2024 Jun;
13(10):2105-2121.
PMID: 38941068
Introduction: Recurrent Clostridioides difficile infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to prevent rCDI following antibiotics...